Abstract The clinical course of a Paroxysmal Nocturnal Hemoglobinuria (PNH) patient receiving treatment with terminal complement by ravulizumab and SARS-CoV2…

Pablo Estival
Hospital Clinico Universitario San Carlos, Department of Hematology, The Clínic Institute of Hematological and Oncological Diseases, Madrid, Spain